A trial of topiramate for patients with hereditary spinocerebellar ataxia

Abstract

Abstract In an open pilot trial, six patients with various hereditary forms of spinocerebellar ataxia (SCA) were assigned to topiramate (50 mg/day) for 24 weeks. Four patients completed the protocol without adverse events. Of these four patients, topiramate was effective for three patients. Some patients with SCA could respond to treatment with topiramate.

Keywords

• drug repositioning
• spinocerebellar ataxia
• topiramate